Actively Recruiting
Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure
Led by Medical University of Graz · Updated on 2025-12-08
266
Participants Needed
3
Research Sites
356 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Venom immunotherapy (VIT) is an established treatment for Hymenoptera venom allergy and provides long-term protection from further generalized reactions in almost all patients. However, it is still unclear why bee VIT is less effective than vespid VIT. The preliminary data show that not only predominant Api m 10 sensitization but also other predominant sensitizations may be relevant as risk factors for treatment failure. Interestingly, all patients with a predominant Api m 10 sensitization who received bee VIT with a venom preparation with a supposed lack of Api m 10 tolerated sting challenges. Therefore, a multicenter study with a sufficient number of patients with treatment failure is urgently required, to clarify if predominant sensitization to a bee venom allergen is a risk factor for treatment failure. If predominant sensitization is a risk factor and caused by underrepresented components in bee venom preparations used for VIT, bee venom preparations may be optimized in the future and patients would benefit from a more effective VIT.
CONDITIONS
Official Title
Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Legally competent male and female subjects aged from 18 to 70 years
- History of a systemic anaphylactic sting reaction (grade I or higher according to Ring and Messmer classification) after bee stings
- Will receive bee venom immunotherapy
You will not qualify if you...
- Contraindications to venom immunotherapy (VIT)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Department of Dermatology and Venerology, Medical University of Graz
Graz, Austria, 8036
Actively Recruiting
2
Elbe Klinikum Buxtehude
Buxtehude, Germany, 21614
Actively Recruiting
3
Hospital Universitario de Castellón
Castellon, Spain, 12004
Actively Recruiting
Research Team
G
Gunter J Sturm, MD, PhD
CONTACT
L
Lisa Arzt-Gradwohl, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here